Urticarial vasculitis - I-Urticarial Vasculitis
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
References
I- Urticarial vasculitis yisimo esingavamile esimakwa iziqephu ezihlala isikhathi eside noma eziphindaphindayo ze-hives. Nakuba izimpawu zesikhumba zingase zifane nezinyosi ezingalapheki, zihlukile ngoba isifuba sinamathela okungenani amahora angu-24 futhi singadala amachashaza amnyama ngemva kokufiphala. Nakuba ngokuvamile kuyimbangela engaziwa, ngezinye izikhathi kungase kubangele imithi ethile, izifo, izifo ezizimele, ukuphazamiseka kwegazi, noma umdlavuza. Ezinye izifundo zize zayixhuma ku-COVID-19 kanye nomkhuhlane we-H1N1. Kungase kuthinte nezinye izingxenye zomzimba njengemisipha, izinso, amaphaphu, isisu namehlo. Nakuba uhlobo oluthile lokuhlolwa kwezicubu lungaqinisekisa ukuxilongwa, akudingekile ngaso sonke isikhathi. Ukwelashwa ngokuvamile kuqala ngama-antibiotics, i-dapsone, i-colchicine, noma i-hydroxychloroquine ezimweni ezibucayi. Ezimweni ezimbi kakhulu, izidakamizwa ezicindezela amasosha omzimba njenge-methotrexate noma i-corticosteroids zingadingeka. Muva nje, izindlela zokwelapha ze-biologic (rituximab, omalizumab, interleukin-1 inhibitors) zibonise ukuthembisa ezimweni ezinzima.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Indoda eneminyaka engu-35 ubudala ifike nomlando wezinsuku ezingu-15 wokuqubuka okubomvu okugqamile, okubuhlungu emathangeni nasemilenzeni, kanye nobuhlungu bamalunga. Ubenegciwane emgudwini womchamo isonto lonke ngaphambi kokuba kuvele ukuqhuma. Isikhumba sakhe sasiveza amabala abomvu ezinhlangothini zombili zamathanga nemilenze yakhe. Wanikezwa i-prednisolone yomlomo (40mg/ngosuku) isonto lonke kanye ne-antihistamine engakozeli (fexofenadine) . Lingakapheli isonto, zonke iziqubu zanyamalala ngokuphelele. Akubanga khona ukuqubuka phakathi nezinyanga eziyisi-6 ezilandelayo zokuhlolwa okuvamile.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
○ Ukwelashwa - Izidakamizwa ze-OTC
Uma unomkhuhlane (ukushisa komzimba okwenyukayo), sincoma ukuthi uthole usizo lwezokwelapha ngokushesha ngangokunokwenzeka.
Umuthi osolwayo kufanele uyekwe. (isb. ama-antibiotics, ama-non-steroidal anti-inflammatory drugs)
Ama-antihistamine omlomo afana ne-cetirizine noma i-loratadine yokulunywa.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]
Amafutha e-OTC steroid angase angasebenzi kumandla aphansi. Idinga ukufakwa isicelo isikhathi esingaphezu kweviki ukuze ubone ukuthuthuka.
#Hydrocortisone ointment